Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Paolo A. Ascierto's publication output changed over time?
ScholarIQpublication output · 2011–2019
Output grew100% over the shown period — from 1 works in 2011 to 2 in 2019.
1
1
2
2
2
20112014201520172019
What are the most-cited papers on Paolo A. Ascierto?
ScholarIQmost cited works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew Hill, John Wagstaff, Matteo S. Carlino, John B.A.G. Haanen, Michele Maio, Iván Márquez‐Rodas, Grant A. McArthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth F. Grossmann, Mario Sznol, Brigitte Dréno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine E. Horak, F. Stephen Hodi, Jedd D. Wolchok
New England Journal of Medicine. 20158,191 CitationsOPEN ACCESS
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert, John B.A.G. Haanen, Paolo A. Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Célèste Lebbé, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven O’Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dréno, K. B. Nolop, Jiang Li, B. Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur
New England Journal of Medicine. 20117,715 CitationsOPEN ACCESS
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, David Hogg, John B.A.G. Haanen, Matteo S. Carlino, Oliver Bechter, Michele Maio, Iván Márquez‐Rodas, Massimo Guidoboni, Grant A. McArthur, Célèste Lebbé, Paolo A. Ascierto, Georgina V. Long, Jonathan Cebon, Jeffrey A. Sosman, Michael A. Postow, Margaret K. Callahan, Dana Walker, Linda Rollin, Rafia Bhore, F. Stephen Hodi, James Larkin
New England Journal of Medicine. 20175,410 CitationsOPEN ACCESS
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, L. Lundgren-Eriksson, Christine E. Horak, Brian J. Sharkey, Ian M. Waxman, Victoria Atkinson, Paolo A. Ascierto
New England Journal of Medicine. 20145,365 CitationsOPEN ACCESS
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, David Hogg, Andrew F. Hill, Iván Márquez‐Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Célèste Lebbé, Grant A. McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Lars Bastholt, Jasmine I. Rizzo, Ágnes Balogh, Andriy Moshyk, F. Stephen Hodi, Jedd D. Wolchok
New England Journal of Medicine. 20193,728 CitationsOPEN ACCESS
Related on ScholarIQ
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
University
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Paper
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paper
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Paper
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Paper
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Paper